Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan.
Department of Mathematics, School of Science, Tokai University, Kanagawa, Japan.
Allergy. 2023 Nov;78(11):2933-2943. doi: 10.1111/all.15820. Epub 2023 Jul 17.
Allergic bronchopulmonary aspergillosis (ABPA) develops in the presence or absence of asthma, either atopic or nonatopic. We have tried to explore the essential components in the pathogenesis of the disease, which are either consistent and variable according to the presence and type of asthma.
Non-cystic fibrosis ABPA cases satisfying Asano's criteria were extracted from a prospective registry of ABPA and related diseases in Japan between 2013 and 2023. According to the type of preceding asthma, ABPA was classified into three groups: ABPA sans asthma (no preceding asthma), ABPA with atopic asthma, and ABPA with nonatopic asthma. Exploratory and confirmatory factor analyses were performed to identify the components that determined the clinical characteristics of ABPA.
Among 106 cases of ABPA, 25 patients (24%) had ABPA sans asthma, whereas 57 (54%) and 24 (23%) had ABPA with atopic and nonatopic asthma, respectively. Factor analysis identified three components: allergic, eosinophilic, and fungal. Patients with atopic asthma showed the highest scores for the allergic component (p < .001), defined by total and allergen-specific IgE titers and lung opacities, and the lowest scores for the fungal component defined by the presence of specific precipitin/IgG or positive culture for A. fumigatus. Eosinophilic components, including peripheral blood eosinophil counts and presence of mucus plugs/high attenuation mucus in the bronchi, were consistent among the three groups.
The eosinophilic component of ABPA is considered as the cardinal feature of ABPA regardless of the presence of preceding asthma or atopic predisposition.
变应性支气管肺曲霉病(ABPA)在存在或不存在哮喘的情况下发生,无论是特应性还是非特应性。我们试图探讨疾病发病机制中的基本成分,这些成分根据哮喘的存在和类型是一致的还是可变的。
从 2013 年至 2023 年在日本进行的 ABPA 和相关疾病的前瞻性登记中提取符合 Asano 标准的非囊性纤维化 ABPA 病例。根据先前哮喘的类型,将 ABPA 分为三组:无哮喘的 ABPA(无先前哮喘)、特应性哮喘的 ABPA 和非特应性哮喘的 ABPA。进行探索性和验证性因子分析,以确定决定 ABPA 临床特征的成分。
在 106 例 ABPA 患者中,25 例(24%)为无哮喘的 ABPA,57 例(54%)和 24 例(23%)为特应性哮喘和非特应性哮喘的 ABPA。因子分析确定了三个成分:过敏、嗜酸性粒细胞和真菌。特应性哮喘患者的过敏成分得分最高(p<0.001),由总 IgE 和过敏原特异性 IgE 滴度和肺部不透射线影定义,真菌成分得分最低,由特定沉淀素/IgG 或 A. fumigatus 的阳性培养定义。三组之间的嗜酸性粒细胞成分,包括外周血嗜酸性粒细胞计数和支气管黏液栓/高衰减黏液的存在,是一致的。
无论是否存在先前的哮喘或特应性倾向,ABPA 的嗜酸性粒细胞成分被认为是 ABPA 的主要特征。